Introduction {#Sec1}
============

The efficacy of ibandronate as a daily treatment regimen was initially demonstrated in the BONE study (oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe) \[[@CR1]\]. Monthly and quarterly dosing regimens of bisphosphonates were subsequently developed with the aim of maintaining adherence and improving outcomes. Based on the bridging strategy, and evidence of an association between bone mineral density (BMD) increases and anti-fracture efficacy \[[@CR2]\], the MOBILE (Monthly Oral iBandronate In LadiEs) and DIVA (Dosing IntraVenous Administration) registration trials were conducted and showed superior BMD increases with monthly oral and quarterly intravenous (IV) ibandronate, respectively, versus the daily oral regimen \[[@CR3]--[@CR5]\]. Increases in BMD at all sites were maintained in long-term extensions of these two trials \[[@CR6], [@CR7]\].

Meta-analyses of these registration trials confirmed the significant efficacy of monthly oral and quarterly IV regimens of ibandronate in risk reduction of not only vertebral fractures but also non-vertebral and clinical fractures \[[@CR8], [@CR9]\]. In addition, a post hoc analysis of individual patient data from the MOBILE and DIVA studies, plus the long-term extensions, revealed a significantly longer time to fracture with intermittent regimens of ibandronate than with placebo over 5 years \[[@CR10]\]. These analyses indicated that ibandronate regimens with an annual cumulative exposure (ACE) ≥10.8 mg (i.e., monthly oral 150 mg, quarterly IV 3 mg/3 months) significantly reduced the risk of non-vertebral fractures, including hip fractures, compared with ibandronate regimens with low ACE or placebo.

In Japan, the development of IV regimens of ibandronate was prioritized and the ACE concept was considered. The phase 3 MOVER (MOnthly intraVenous ibandronatE versus daily oral Risedronate) study, conducted for registration purposes in Japan, was designed to demonstrate the non-inferiority of IV ibandronate 1 mg/month (ACE of 12.0 mg) to oral risedronate in vertebral fracture risk reduction. Results of the study showed that IV ibandronate 1 mg/month consistently reduced the incidence of not only vertebral fractures but also non-vertebral fractures, compared with risedronate \[[@CR11]\]. Conversely, the optimal dose of monthly oral ibandronate in Japanese osteoporotic patients has not yet been determined. However, the oral 150 mg/month dose is widely used in Western countries with Caucasian (or non-Asian) patients with osteoporosis. The licensed oral doses of alendronate and risedronate for the treatment of osteoporosis in Japan are half those given in Western countries \[[@CR12]--[@CR17]\], whereas the results of the phase 2 dose-finding study with monthly oral ibandronate showed that 100 mg was considered to be the optimal dose for Japanese patients \[[@CR18]\].

The purpose of the current registration study was to examine the efficacy and safety of monthly oral ibandronate 100 mg for Japanese patients with osteoporosis and to demonstrate its non-inferiority versus monthly IV ibandronate 1 mg in terms of BMD increases after 12 months of treatment.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

The MOVEST (Monthly Oral VErsus intravenouS ibandronaTe) study was a prospective, multicenter, randomized, double-blinded, double-dummy comparative study that compared oral ibandronate 100 mg/month with IV ibandronate 1 mg/month in Japanese women and men with osteoporosis (Clinical trial number JapicCTI-121982). The primary endpoint was the non-inferiority of oral ibandronate versus IV ibandronate with respect to lumbar spine BMD (L2--L4) gains after 12 months of treatment.

Patients {#Sec4}
--------

Japanese women and men aged ≥55 years with primary osteoporosis according to the Diagnosis Criteria of Primary Osteoporosis in Japan \[[@CR19]\] were eligible. Patients were required to have BMD of the lumbar spine (L2--L4) \<70 % of the young adult mean (T score less than −2.6 standard deviations \[SD\]) or BMD of the lumbar spine (L2--L4) \<80 % of the YAM (T score less than −1.7 SD) with fragile bone fracture (non-traumatic osteoporotic fracture that occurred by slight external force combined with low BMD).

Exclusion criteria included vertebral deformations likely to affect lumbar spine (L2--L4) BMD measurements by dual-energy x-ray absorptiometry (DXA) scan in central review; previous radiotherapy of the thoracic spine/lumbar spine/pelvis; secondary osteoporosis or a disease causing decrease in bone volume; a disorder delaying the passage of food through the esophagus; received/planned invasive dental procedures; bisphosphonate use within 1 year of the start of the study, anti-receptor activator of nuclear factor-κB ligand (RANKL) antibody (AMG162) use within 2 years of the start of the study, or prior treatment with ibandronate, zoledronate, cathepsin K inhibitor, anti-sclerostin antibody, parathyroid hormone, or strontium; receipt of drugs likely to affect bone metabolism within 8 weeks of the start of the study; severe cardiac, renal, or hepatic disease; calcium outside the criteria value (\<8.4 or \>10.4 mg/dL); hypersensitivity to bisphosphonate, calcium, or vitamin D; and active malignant tumor or prior therapy for malignant tumor within 3 years.

Treatment {#Sec5}
---------

Patients were randomly assigned to receive 100 mg/month oral ibandronate (F. Hoffmann-La Roche, Ltd.) plus IV placebo, or 1 mg/month IV ibandronate (F. Hoffmann-La Roche, Ltd.) plus oral placebo for 12 months by the double dummy method. Patients were instructed to take ibandronate or placebo tablets 60 min before their first food or drink of the day, swallowed whole with a full glass of water while sitting or standing in an upright position. All patients received supplementary calcium 610 mg and vitamin D 400 IU/day from the registration date until the end of the study. Study drug administration was recorded by the investigator at the time of dosing.

Randomization and blinding {#Sec6}
--------------------------

Randomization was performed centrally through dynamic allocation (minimization method) based on the patient's L2--L4 BMD value at screening (T-score \<−3.0 vs. ≥−3.0). Patients, investigators, steering committee members, the sponsor, and the faculty who adjudicated the study endpoints remained unaware of treatment-group assignments throughout the trial.

Study endpoints {#Sec7}
---------------

The primary endpoint was the percentage change from baseline in lumbar spine (L2--L4) BMD at 12 months. Secondary endpoints were the percentage change from baseline in total hip, femoral neck, and trochanter BMD; change from baseline in bone turnover markers (BTMs) of urinary C-telopeptide of type 1 collagen corrected by creatinine (uCTX), serum tartrate-resistant acid phosphatase 5b (TRAP 5b), urinary N-telopeptide of type 1 collagen corrected by creatinine (uNTX), serum procollagen type 1N-terminal propeptide (P1NP), and serum bone-specific alkaline phosphatase (BALP); incidences of non-traumatic new vertebral or non-vertebral fractures; and safety.

Schedule of assessments {#Sec8}
-----------------------

BMD measurements at the lumbar spine (L2--L4), total hip, femoral neck, and trochanter were performed centrally (BioClinica, Newark, CA, USA) at screening, baseline, 4, 6, and 12 months using DXA of Hologic bone densitometers. Measurements of a quality control phantom were collected and analyzed by BioClinica to monitor the stability of each DXA scanner. Each study site received the cross-calibration phantom and cross-calibration scans were sent to BioClinica for processing and statistical analysis. BTMs were measured centrally (LSI Medience Corporation, Tokyo, Japan) at baseline, 1, 3, 6, and 12 months. All samples were obtained under fasting conditions prior to study drug administration.

Radiographs of the thoracic and lumbar spine were taken at screening, baseline, and at 12 months after treatment for the assessment of fracture incidence. To identify morphometric vertebral fractures, the vertebral bodies of the lateral projection from Th4 to L4 were assessed using semiquantitative (SQ) methodology by a central committee who were blinded to treatment. A vertebral fracture was defined as an increase of ≥1 SQ grading scale in a vertebra from baseline. Radiographs were assessed by investigators to identify non-vertebral fractures in patients with clinical symptoms.

Adverse events (AEs) were collected throughout the study period and for up to 28 days after the end of treatment. AEs of interest such as renal, cardiac, and gastrointestinal (GI) disorders, esophageal irritation, acute phase reactions (APRs; occurring within 3 days of dosing and lasting for no longer than 7 days), hypocalcemia, osteonecrosis of the jaw, and atypical fracture of the femur were specified in advance.

Statistical analyses {#Sec9}
--------------------

The primary analysis was performed on the per-protocol set (PPS). Analyses of BMD and BTMs were analyzed on the relative change from baseline. Missing data were imputed by the last observation carried forward method. An analysis of covariance was used for the comparison of the relative change in BMD gains at the lumbar spine at 12 months between the two treatment groups with covariates as the BMD and P1NP values at baseline, interaction of BMD values at baseline, prior therapy with bisphosphonates and other osteoporotic agents except bisphosphonates. The covariates, except BMD values at baseline, were added based on a blind review of data. The non-inferiority limit for oral ibandronate to IV ibandronate was set at −1.6. If the lower limit of the 95 % confidence interval (CI) of the least squares mean difference was above the non-inferiority limit, the non-inferiority of oral ibandronate to IV ibandronate would be concluded.

Based on analyses in the MOVER study \[[@CR11]\], the relative change in lumbar spine BMD (L2--L4) between oral and IV ibandronate after 12 months of treatment was estimated to be comparable and its SD was estimated to be 4.5 %. The non-inferiority margin was set within 1.6 %, with a one-sided significance level of 0.05 and a detection power of 90 %. With an expected drop-out rate of 15 %, 168 patients were required in each treatment group for analysis, and 198 patients were targeted for registration purposes.

Results {#Sec10}
=======

Patient disposition and baseline characteristics {#Sec11}
------------------------------------------------

A total of 422 patients were enrolled. Fourteen patients did not receive any study drug, leaving 205 and 203 patients (198 and 199 women) in the safety population who were randomized to receive oral ibandronate 100 mg/month and IV ibandronate 1 mg/month, respectively (Fig. [1](#Fig1){ref-type="fig"}). Overall, 177 and 184 patients in the oral and IV ibandronate groups, respectively, completed the study. The PPS for the primary endpoint analysis comprised 183 and 189 patients in the oral 100 mg/month and IV 1 mg/month groups, respectively. Baseline patients' characteristics between the two treatment groups were well balanced (Table [1](#Tab1){ref-type="table"}).Fig. 1Patient flow through the study. *IV* intravenousTable 1Baseline patient characteristicsCharacteristicIbandronateOral 100 mg/month (*n* = 183)IV 1 mg/month (*n* = 189)Women, *n* (%)177 (96.7)186 (98.4)Age, years (SD)68.8 (6.94)69.3 (6.02) 55--74 years, *n* (%)138 (75.4)156 (82.5) ≥75 years, *n* (%)45 (24.6)33 (17.5)Weight, kg (SD)49.5 (7.2)49.2 (6.7)Height, cm (SD)152.2 (6.5)151.6 (6.1)BMD T-score (SD) Lumbar spine (L2--L4)−3.09 (0.58)−3.14 (0.60) Total hip−2.41 (0.84)−2.47 (0.79) Femoral neck−2.98 (0.82)−2.99 (0.78)Prevalent vertebral fractures, *n* (%) 0124 (67.8)130 (68.8) 134 (18.6)34 (18.0) ≥225 (13.7)25 (13.2)uCTX, μg/mmol CR (SD)247.9 (138.8)249.4 (166.4)TRAP 5b, mU/dL (SD)387.4 (131.6)389.2 (152.8)P1NP, μg/L (SD)50.6 (21.36)49.0 (22.30)BALP, μg/L (SD)17.1 (6.78)16.5 (6.91)25-OH(D), ng/mL (SD)25.3 (6.26)25.3 (5.84)Values are the mean, except where indicated*BALP* bone-specific alkaline phosphatase, *BMD* bone mineral density, *CR* creatinine, *IV* intravenous, *P1NP* procollagen type 1N-terminal propeptide, *SD* standard deviation, *TRAP 5b* tartrate-resistant acid phosphatase 5b, *uCTX* creatinine-corrected urinary collagen type 1 cross-linked C-telopeptide, *25-OH(D)* 25-hydroxyvitamin D

Bone mineral density {#Sec12}
--------------------

Similar BMD gains were observed with the two treatment regimens throughout the study. The mean relative change from baseline in lumbar spine BMD at 12 months was 5.22 % (95 % CI 4.65, 5.80) and 5.34 % (95 % CI 4.78, 5.90) with oral and IV ibandronate, respectively (Fig. [2a](#Fig2){ref-type="fig"}). The least squares mean difference between the two groups was −0.23 % (95 % CI −0.97, 0.51), showing the non-inferiority of oral ibandronate 100 mg/month to IV ibandronate 1 mg/month (non-inferiority limit = −1.60). Sensitivity analysis showed that the result of the primary analysis was robust with or without the added covariates (data not shown). Mean relative changes from baseline to 12 months in total hip BMD were 2.41 % (95 % CI 1.95, 2.87) with oral ibandronate and 2.76 % (95 % CI 2.33, 3.19) with IV ibandronate (Fig. [2b](#Fig2){ref-type="fig"}), and in femoral neck BMD were 2.58 % (95 % CI 1.87, 3.29) and 2.64 % (95 % CI 2.06, 3.23), respectively (Fig. [2c](#Fig2){ref-type="fig"}). BMD responder rates at the lumbar spine, total hip, and femoral neck were consistent between the two groups after 12 months of treatment (Table [2](#Tab2){ref-type="table"}).Fig. 2Mean relative change from baseline to 12 months (with 95 % CI) in BMD at the **a** lumbar spine (L2--L4), **b** total hip, and **c** femoral neck. *BMD* bone mineral density, *CI* confidence interval, *IV* intravenousTable 2Responder rates (with 95 % CI) after 12 months of treatmentResponder rate^a^ (%)IbandronateOral 100 mg/monthIV 1 mg/monthPatients with \>0 % increase in BMD L2--L491.8 (86.8, 95.3)92.1 (87.2, 95.5) Total hip86.2 (80.3, 90.9)91.5 (86.6, 95.1) Femoral neck71.3 (64.1, 77.7)74.1 (67.2, 80.2)Patients with ≥3 % increase in BMD L2--L471.6 (64.5, 78.0)75.7 (68.9, 81.6) Total hip39.2 (32.1, 46.7)43.4 (36.2, 50.8) Femoral neck43.1 (35.8, 50.6)41.8 (34.7, 49.2)*BMD* bone mineral density, *CI* confidence interval, *IV* intravenous^a^Defined as the proportion of patients with mean lumbar spine (L2--L4), total hip, or femoral neck BMD above baseline

Bone turnover markers {#Sec13}
---------------------

The mean relative change from baseline in uCTX, serum TRAP 5b, and uNTX levels as bone resorption markers, and in serum P1NP and serum BALP, was similar throughout 12 months of oral and IV ibandronate treatment (Fig. [3](#Fig3){ref-type="fig"}, uNTX data not shown). The decrease from baseline in uCTX levels at 12 months was 62.80 % (95 % CI 56.62, 68.97) with oral ibandronate and 59.51 % (95 % CI 53.70, 65.33) with IV ibandronate (Fig. [3a](#Fig3){ref-type="fig"}). The decrease in TRAP 5b levels was 46.42 % (95 % CI 43.99, 48.85) and 44.65 % (95 % CI 41.84, 47.45), respectively (Fig. [3b](#Fig3){ref-type="fig"}). Decreases in serum P1NP were 68.98 % (95 % CI 66.95, 71.02) and 66.66 % (95 % CI 63.45, 69.87), respectively, with oral and IV ibandronate (Fig. [3c](#Fig3){ref-type="fig"}), and in serum BALP were 47.28 % (95 % CI 45.03, 49.53) and 43.35 % (95 % CI 40.30, 46.40), respectively (Fig. [3d](#Fig3){ref-type="fig"}).Fig. 3Mean relative change from baseline to 12 months (with 95 % CI) in **a** uCTX, **b** serum TRAP 5b, **c** serum P1NP, and **d** serum BALP. *BALP* bone-specific alkaline phosphatase, *CI* confidence interval, *IV* intravenous, *P1NP* procollagen type 1N-terminal propeptide, *TRAP 5b* tartrate-resistant acid phosphatase 5b, *uCTX* creatinine-corrected urinary collagen type 1 cross-linked C-telopeptide

Fractures {#Sec14}
---------

No differences in fracture incidence were observed between the two treatment groups. The incidence of vertebral fracture over 12 months was 1.1 % (2/183) with oral ibandronate and 0.5 % (1/189) with IV ibandronate. The cumulative incidences of non-vertebral fractures over 12 months were 1.1 % (2/183) and 2.6 % (5/189), respectively.

Adverse events {#Sec15}
--------------

No apparent differences were observed between the two treatment groups with respect to the incidence of all AEs, all drug-related AEs, or AEs leading to withdrawal (Table [3](#Tab3){ref-type="table"}). The incidence of GI-related AEs was 12.2 and 9.9 % in the oral and IV ibandronate groups, respectively. The incidence of APRs was also similar between the two groups: 11.2 and 11.8 % in the oral and IV ibandronate groups, respectively. However, APR AEs in the oral ibandronate group were mild in intensity, except for three moderate cases (one bone pain and two APR as preferred term), and all APR AEs in the IV ibandronate group were mild. In both treatment groups, APR AEs were transient and decreased with each subsequent dose of medication (Supplementary Fig. [1](#Fig4){ref-type="supplementary-material"}). As AEs of special interest, the incidence of esophageal irritation-related AEs was 1.0 and 2.5 % with oral and IV ibandronate, respectively. There were no renal function-related AEs, hypocalcemia, osteonecrosis of the jaw, or atypical fracture of the femur (Table [3](#Tab3){ref-type="table"}).Table 3Summary of adverse eventsAE, *n* (%)IbandronateOral 100 mg/month (*n* = 205)IV 1 mg/month (*n* = 203)Any AE175 (85.4)177 (87.2)Drug-related AE47 (22.9)38 (18.7)Severe intensity AE2 (1.0)0Serious AE9 (4.4)6 (3.0)AEs leading to death00AEs leading to treatment withdrawal4 (2.0)4 (2.0)AEs occurring in ≥5 % of patients in either group Nasopharyngitis48 (23.4)62 (30.5) Back pain22 (10.7)24 (11.8) Contusion17 (8.3)13 (6.4) Osteoarthritis12 (5.9)4 (2.0) Muscle pain4 (2.0)11 (5.4)AEs of special interest GI related25 (12.2)20 (9.9)  Esophageal irritation2 (1.0)5 (2.5) APR^a^ related23 (11.2)24 (11.8)  Back pain7 (3.4)6 (3.0)  APR5 (2.4)4 (2.0)  Malaise5 (2.4)2 (1.0)  Arthralgia2 (1.0)4 (2.0)  Myalgia04 (2.0) Renal function related00 Hypocalcemia00 Osteonecrosis of the jaw^b^00 Atypical fracture of the femur^b^00*AE* adverse event, *APR* acute phase reaction, *GI* gastrointestinal, *IV* intravenous^a^Occurring within 3 days of dosing and lasting for no longer than 7 days; APR AEs occurring at an incidence of ≥2 % of patients in either treatment group are listed^b^As per the American Society of Bone and Mineral Research case definition

Discussion {#Sec16}
==========

We compared the efficacy and safety of oral 100 mg/month and IV 1 mg/month ibandronate in terms of changes in BMD and BTMs in Japanese patients with primary osteoporosis for registration purposes. Oral ibandronate was non-inferior to IV ibandronate with respect to lumbar spine BMD gains after 12 months of treatment. BMD gains at femur sites and BTM suppression with oral ibandronate were consistent with those of IV ibandronate. The safety profile of oral ibandronate was comparable not only with that of IV ibandronate but also with that of previously examined intermittent ibandronate regimens \[[@CR1], [@CR3], [@CR6]\]. The oral ibandronate regimen was well tolerated.

BMD gains have been recognized as a surrogate marker for future fracture risk. The relationship between increases in BMD and fracture risk reduction by treatment with ibandronate has been reported previously \[[@CR20], [@CR21]\]. Patients receiving ibandronate at high ACE (10.8--12.0 mg) showed higher BMD increases and stronger anti-fracture efficacy than those treated at low ACE (5.5 mg) \[[@CR9]\]. In the MOVER study, IV ibandronate 1 mg/month (ACE of 12.0 mg) demonstrated non-inferiority to risedronate in terms of vertebral fracture risk reduction \[[@CR11]\]. The fact that the oral ibandronate 100 mg/month regimen was bridged to the IV 1 mg/month regimen in this study suggests that monthly oral ibandronate 100 mg would be efficacious in fracture risk reduction.

Nakai et al. recently reported that the area under the ibandronate serum-concentration time curve (AUC) and the relative change in uCTX levels with oral ibandronate 100 mg/month were comparable with those of IV ibandronate 1 mg/month in Japanese postmenopausal women \[[@CR22]\]. The optimal monthly dose of ibandronate for Japanese patients was confirmed as 100 mg, based on the results of the phase 2 dose-finding study \[[@CR18]\] and the current pivotal bridging clinical trial. The optimal monthly dose for Caucasian patients in Western countries is 150 mg, which is higher than that for Japanese patients. The bioavailability of oral ibandronate is reported to be 0.63 % in Western populations \[[@CR23]\] and 0.91 % in Japanese populations \[[@CR22]\]. This 1.44-times higher bioavailability in Japanese patients could lead to a 1.5-times higher optimal dose in Western patients. In fact, the bioavailability of bisphosphonates, including risedronate, in Japanese patients has been reported to be slightly higher than in Western populations \[[@CR24]--[@CR26]\]. The reason for this difference in bioavailability is still unknown \[[@CR22]\]. Overall, exposure to ibandronate is similar in Japanese and Western populations because of dose optimization in the different settings. This suggests that oral ibandronate, when dosed optimally, offers similar efficacy and safety benefits to Japanese and Western patients.

The safety profile of ibandronate in this current study was similar to previous studies in Western patients with no apparent increase in the nature or severity of AEs. APR is commonly experienced following the first administration of nitrogen-containing bisphosphonates. The incidence of APR AEs was similar with monthly oral and IV ibandronate, administered at comparable ACE, and they were reported at a similar frequency to previous studies \[[@CR3], [@CR4], [@CR11]\]. The incidence of GI-related AEs was also similar between the treatment groups. Thus, oral ibandronate 100 mg/month appears to be well tolerated by Japanese osteoporotic patients with a similar safety profile to the established monthly oral regimen in Western populations.

There are some limitations to this study. Firstly, regarding concerns about GI-related AEs with oral bisphosphonate treatment, the incidence of these AEs in the current study may not reflect the effects seen in daily practice due to the double dummy design used. In addition, we assessed fracture incidence over 12 months of treatment, but there are as yet limited data on the fracture incidence with 100 mg/month ibandronate in Japanese patients over longer treatment periods. Further clinical evidence must be accumulated on long-term treatment duration in this patient population.

Better adherence to treatment can lead to improved outcomes in patients with osteoporosis, both in terms of BMD gains and in fracture risk reduction. Although bisphosphonates have been used as first-line therapy for many years, their complex dosing instructions have resulted in adherence issues with long-term treatment. Adherence is higher with weekly rather than daily bisphosphonates \[[@CR27]\] and with monthly rather than weekly treatment \[[@CR28], [@CR29]\]. A preference for monthly oral bisphosphonates has also been reported \[[@CR30], [@CR31]\]. These findings suggest that the availability of a monthly oral ibandronate dosing regimen would create an opportunity to improve adherence in Japanese patients with osteoporosis.

In conclusion, oral ibandronate 100 mg/month demonstrated non-inferiority to IV ibandronate 1 mg/month (licensed dose in Japan) in lumbar spine BMD gains in Japanese patients with primary osteoporosis. The safety profile of oral and IV ibandronate was similar, and monthly oral ibandronate was as well tolerated in Japanese patients as in Western patients. These data suggest that these two different monthly ibandronate regimens are effective alternatives for the treatment of osteoporosis in Japanese patients.
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